Fuyu Tamanoi is a biochemist who has served on the UCLA School of Medicine and UCLA College faculty since he joined the Department of Microbiology, Immunology & Molecular Genetics in 1993. He became a full professor in 1997.

• Discovery of Small-Molecule Ras Inhibitors that Display Anti-Tumor Activity by Interfering with Ras•GTP-Effector InteractionFumi Shima, Yoko Yoshikawa, Shigeyuki Matsumoto and Tohru KataokaAn Orthosteric Inhibitor of the RAS-SOS InteractionSeth Nickerson, Stephen T. Joy, Paramjit S. Arora and Dafna Bar-Sagi Conformation-Specific Inhibitors of Raf kinasesXiaolun Wang and Kristin SchleicherInhibitors of the ERK Mitogen-activated Protein Kinase Cascade for Targeting RAS Mutant CancersLeanna Gentry, Ahmed A. Samatar and Channing J. DerInhibiting the RAS - PI3K Pathway in Cancer TherapyClare Sheridan and Julian DownwardThe RalGEF/Ral Pathway: Evaluating an Intervention Opportunity for Ras CancersJonathan M. Cooper, Brian O. Bodemann and Michael A. Whitep21-Activated Kinase InhibitorsJoachim Rudolph, James J. Crawford, Klaus P. Hoeflich, and Jonathan ChernoffRecent Progress in Developing Small Molecule Inhibitors Designed to Interfere with Ras Membrane Association: Towards Inhibiting K-Ras and N-Ras Functions Fuyuhiko Tamanoi and Jie LuSynthetic Lethal Genetic Screens in Ras Mutant CancersBing Yu and Ji Luo

Fuyu Tamanoi is a biochemist who has served on the UCLA School of Medicine and UCLA College faculty since he joined the Department of Microbiology, Immunology & Molecular Genetics in 1993. He became a full professor in 1997.

• Discovery of Small-Molecule Ras Inhibitors that Display Anti-Tumor Activity by Interfering with Ras•GTP-Effector InteractionFumi Shima, Yoko Yoshikawa, Shigeyuki Matsumoto and Tohru KataokaAn Orthosteric Inhibitor of the RAS-SOS InteractionSeth Nickerson, Stephen T. Joy, Paramjit S. Arora and Dafna Bar-Sagi Conformation-Specific Inhibitors of Raf kinasesXiaolun Wang and Kristin SchleicherInhibitors of the ERK Mitogen-activated Protein Kinase Cascade for Targeting RAS Mutant CancersLeanna Gentry, Ahmed A. Samatar and Channing J. DerInhibiting the RAS - PI3K Pathway in Cancer TherapyClare Sheridan and Julian DownwardThe RalGEF/Ral Pathway: Evaluating an Intervention Opportunity for Ras CancersJonathan M. Cooper, Brian O. Bodemann and Michael A. Whitep21-Activated Kinase InhibitorsJoachim Rudolph, James J. Crawford, Klaus P. Hoeflich, and Jonathan ChernoffRecent Progress in Developing Small Molecule Inhibitors Designed to Interfere with Ras Membrane Association: Towards Inhibiting K-Ras and N-Ras Functions Fuyuhiko Tamanoi and Jie LuSynthetic Lethal Genetic Screens in Ras Mutant CancersBing Yu and Ji Luo

Fuyu Tamanoi is a biochemist who has served on the UCLA School of Medicine and UCLA College faculty since he joined the Department of Microbiology, Immunology & Molecular Genetics in 1993. He became a full professor in 1997.

• Discovery of Small-Molecule Ras Inhibitors that Display Anti-Tumor Activity by Interfering with Ras•GTP-Effector InteractionFumi Shima, Yoko Yoshikawa, Shigeyuki Matsumoto and Tohru KataokaAn Orthosteric Inhibitor of the RAS-SOS InteractionSeth Nickerson, Stephen T. Joy, Paramjit S. Arora and Dafna Bar-Sagi Conformation-Specific Inhibitors of Raf kinasesXiaolun Wang and Kristin SchleicherInhibitors of the ERK Mitogen-activated Protein Kinase Cascade for Targeting RAS Mutant CancersLeanna Gentry, Ahmed A. Samatar and Channing J. DerInhibiting the RAS - PI3K Pathway in Cancer TherapyClare Sheridan and Julian DownwardThe RalGEF/Ral Pathway: Evaluating an Intervention Opportunity for Ras CancersJonathan M. Cooper, Brian O. Bodemann and Michael A. Whitep21-Activated Kinase InhibitorsJoachim Rudolph, James J. Crawford, Klaus P. Hoeflich, and Jonathan ChernoffRecent Progress in Developing Small Molecule Inhibitors Designed to Interfere with Ras Membrane Association: Towards Inhibiting K-Ras and N-Ras Functions Fuyuhiko Tamanoi and Jie LuSynthetic Lethal Genetic Screens in Ras Mutant CancersBing Yu and Ji Luo